70% of the $1.3M in #$IOVA options premium on Nov 13 went to puts.
Volume that far above open interest points to new positions being opened.
Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
70% of the $1.3M in #$IOVA options premium on Nov 13 went to puts.
Volume that far above open interest points to new positions being opened.
Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
Off-exchange shares (share of volume): Nov 13 4,557,124 (39.0%).
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Full story at the link.
#darkpool #stocks #stockmarket
Off-exchange shares (share of volume): Nov 13 4,557,124 (39.0%).
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Full story at the link.
#darkpool #stocks #stockmarket
Hub: https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=iova
Not investment advice.
Hub: https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=iova
Not investment advice.
Roche Corleen M. (Chief Financial Officer) reported special transactions (Non-P/S).
Roche Corleen M. (Chief Financial Officer) reported special transactions (Non-P/S).
• Holder: State Street
• Stake: 0 → 4.8% (about $175M)
• About 13G: a passive investor, not seeking to influence the company
• Filed: Nov 10 · Schedule 13G
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: State Street
• Stake: 0 → 4.8% (about $175M)
• About 13G: a passive investor, not seeking to influence the company
• Filed: Nov 10 · Schedule 13G
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
#$IOVA FAQ + PDF: www.merlintrader.com/iovance-biot...
#$IOVA FAQ + PDF: www.merlintrader.com/iovance-biot...
https://youtu.be/Nw5mwWtuteM?list=RDNw5mwWtuteM...
https://artblack.name/2026/11/06/solar-is-kniga-iova/
https://youtu.be/Nw5mwWtuteM?list=RDNw5mwWtuteM...
https://artblack.name/2026/11/06/solar-is-kniga-iova/
On November 5, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.
On November 5, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.
https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
On November 5, 2026, Iovance Biotherapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026, and an update on recent developments.
On November 5, 2026, Iovance Biotherapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026, and an update on recent developments.
https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-reports-record-third-quarter-2026-revenue-of-jbnkoph7isi0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-reports-record-third-quarter-2026-revenue-of-jbnkoph7isi0.html?utm_source=stocktitan-bluesky&utm_medium=social
- U.S. Amtagvi revenue ~$102M; 1,000+ patients commercially treated
- Gross margin hits all-time high ~60%; R&D spend down 34% YoY
- Lung cancer trial: 24.6% ORR overall, 59.1% in biomarker-selected patients
- U.S. Amtagvi revenue ~$102M; 1,000+ patients commercially treated
- Gross margin hits all-time high ~60%; R&D spend down 34% YoY
- Lung cancer trial: 24.6% ORR overall, 59.1% in biomarker-selected patients
$GDYN +59.0%
$REPL +56.3%
$ULCC +51.3%
$DRUG -48.7%
$IOVA -41.8%
$OFRM -40.7%
$GDYN +59.0%
$REPL +56.3%
$ULCC +51.3%
$DRUG -48.7%
$IOVA -41.8%
$OFRM -40.7%
#$IOVA weekly close $8.48 (-39.8% w/w), below SMA50 $11.37 / above SMA200 $5.84, RSI 30.4.
IOVA Stock Hub: Iovance News, Amtagvi and Clinical Data
www.merlintrader.com/iovance-biot...
#$IOVA weekly close $8.48 (-39.8% w/w), below SMA50 $11.37 / above SMA200 $5.84, RSI 30.4.
IOVA Stock Hub: Iovance News, Amtagvi and Clinical Data
www.merlintrader.com/iovance-biot...
Scan for them yourself, free: glsequity.com/scanners
Scan for them yourself, free: glsequity.com/scanners